As in­sulin prices sky­rock­et, Michi­gan law­mak­ers look to make it in-state

If Cal­i­for­nia can fig­ure out a way to low­er in­sulin prices for its res­i­dents, why can’t Michi­gan do the same?

That’s the mind­set of a group of state law­mak­ers, in­clud­ing Sen. Curt Van­der­Wall, R-Lud­ing­ton. The group has met with drug­mak­ers — in­clud­ing Pfiz­er — and lo­cal uni­ver­si­ties to talk about what it would take to cut the cost of in­sulin for res­i­dents with di­a­betes.

Curt Van­der­Wall

In an in­ter­view with Bridge Michi­gan, Van­der­Wall said that there are two main av­enues to ex­plore. One in­volves bring­ing man­u­fac­tur­ers to the ta­ble and get­ting them to of­fer to sell the drugs at cost. The oth­er in­volves tak­ing the state, and turn­ing it in­to a man­u­fac­tur­er it­self.

In­sulin has been around 100 years, but the prices have sky­rock­et­ed in the 21st cen­tu­ry. Re­search from GoodRx shows that the av­er­age re­tail price for in­sulin rose 54% from 2014 to 2019. This is due, in part, to the lack of com­pe­ti­tion, as three com­pa­nies —No­vo Nordisk, Sanofi, and Eli Lil­ly— pro­vide all of the in­sulin to the US.

Van­der­Wall has spo­ken with both the Uni­ver­si­ty of Michi­gan and Michi­gan State about man­u­fac­tur­ing drugs through their cam­pus­es. A spokesper­son con­firmed those ear­ly talks. The state once had its own drug man­u­fac­tur­ing fa­cil­i­ty, as it was start­ed back in the 1920s, but that was sold in 1998 to Bio­Port, now Emer­gent BioSo­lu­tions.

Oth­er states have tak­en a stab at curb­ing the steep prices. Col­orado in­stalled a price cap on in­sulin in 2019, and Neva­da passed a man­dat­ed price trans­paren­cy law in 2017. Most fa­mous­ly, Cal­i­for­nia Gov. Gavin New­som has re­peat­ed­ly said that his state is mov­ing to­ward pro­vid­ing res­i­dents with low-cost in­sulin. In Jan­u­ary, he an­nounced that the state was work­ing on a part­ner­ship that would make the drug at a “pro­found­ly re­duced” price, though no specifics were di­vulged. Blue Shield of Cal­i­for­nia joined the ini­tia­tive in March, part­ner­ing with Civi­ca to help man­u­fac­ture gener­ics that could cost $30 or less per vial. That isn’t ex­pect­ed to be avail­able un­til 2024, how­ev­er.

This isn’t Van­der­Wall’s first for­ay in­to pre­scrip­tion drugs. As the chair of the Health Pol­i­cy and Hu­man Ser­vices Com­mit­tee, he cel­e­brat­ed the pass­ing of HB 4348 in Feb­ru­ary. The bill al­lows phar­ma­cies to of­fer more af­ford­able pre­scrip­tion drugs to those in need.

So­cial: Michi­gan State Capi­tol (shut­ter­stock)

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

15 LGBTQ lead­ers in bio­phar­ma; Paul Stof­fels’ Gala­pa­gos re­vamp; As­traZeneca catch­es up in AT­TR; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

A return to in-person conferences also marks a return to on-the-ground reporting. My colleagues Beth Synder Bulik and Nicole DeFeudis were on-site at Cannes Lions, bringing live coverage of pharma’s presence at the ad festival — accompanied by photos from Clara Bui, our virtual producer, that bring you right to the scene. You can find a recap (and links to all the stories) below.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

David Loew (Ipsen)

Ipsen snags an ap­proved can­cer drug in $247M M&A deal as an­oth­er bat­tered biotech sells cheap

You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal.

The French biotech, which has had plenty of its own problems to grapple with, has swooped in to buy Epizyme $EPZM for $247 million in cash and a CVR with milestones attached to it. Epizyme shareholders, who had to suffer through a painfully soft launch of their EZH2a inhibitor cancer drug Tazverik, will get $1.45 per share along with a $1 CVR tied to achieving $250 million in sales from the drug over four consecutive quarters as well as an OK for second-line follicular lymphoma by 1 Jan. 2028.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

Sen. Thom Tillis (R-NC) (J. Scott Applewhite/AP Images)

Phar­ma-friend­ly sen­a­tor calls on FDA for a third time to show patent pro­tec­tions should­n't be blamed for high drug prices

North Carolina Republican Sen. Thom Tillis made a name for himself in the 2020 election cycle as the darling of the pharma industry, accepting hundreds of thousands in campaign contributions, even from the likes of Pfizer CEO Albert Bourla.

Those contributions have led Tillis to attempt to re-write patent laws in pharma’s favor, a move which failed to gain steam in 2019, and request for a third time since January that the FDA should help stop “the false narrative that patent protections are to blame for high drug prices.”

EMA signs off on 3 drugs re­cent­ly re­ject­ed by FDA, in­clud­ing Bio­Mar­in's new he­mo­phil­ia gene ther­a­py

The EMA’s human medicines committee on Friday recommended three new drugs for approval or conditional approval, even as their US counterparts have rejected these three for various reasons.

In a major move, CHMP offered a thumbs-up to a conditional marketing authorization for the first gene therapy to treat severe hemophilia A, although the agency cautioned that it’s so far unknown how long the effects of infusion will last.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Joe Papa (Ryan Remiorz/The Canadian Press via AP, File)

Joe Pa­pa re­signs as chair of Bausch Health as bil­lion­aire John Paul­son takes over

Joe Papa, chair of Bausch Health, officially resigned on Thursday and the board appointed billionaire hedge fund manager John Paulson as the new chair, effective immediately.

The specialty pharma company sought to make clear that Papa’s abrupt departure “was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.